“Among eight patients with hepatitis C genotype 1, the most common form of the disease in the U.S., six had a viral relapse within four weeks after stopping a 12-week regimen with the medicine, GS-7977, plus ribavirin, Gilead said today in a statement. The other patients in the trial are two weeks out from stopping treatment, and haven’t relapsed, the company said.”—Read more: Gilead Drops as Patients Relapse on Hepatitis C Drug - Businessweek
During February’s observance of African American History Month, please join HHS in working to end the unfortunate history of viral hepatitis’ disproportionate impact on the African American community. The Obama Administration is working hard to reduce and eliminate health disparities and achieve health equity.
The new national helpline can be reached toll-free at 877-HELP-4-HEP (877-435-7443), via email at firstname.lastname@example.org, or on the web at www.help4hep.org. The phone helpline is staffed Monday through Friday, 9 am to 7 pm EST (6 am to 4 pm PST).
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)–boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6. Read more here.
“Hepatitis is a problem that is important to us and President Obama, the first president to publicly acknowledge that chronic viral hepatitis is a national concern,” said Chris Lu, White House Cabinet Secretary and Co-chair, White House Initiative on Asian Americans and Pacific Islanders. “Hep B is a problem that disproportionately affects our API community. It’s important to raise public awareness of the importance of early detection.”—White House Pledges Support to End Viral Hepatitis
“Today, more than 4 million Americans are infected with hepatitis C and the vast majority does not know it," said Dr. Willis C. Maddrey, President of the Chronic Liver Disease Foundation. "Hepatitis C is a leading cause of chronic liver disease, cirrhosis and liver cancer. However, new therapies are now available that can effectively treat a high percentage of people with HCV infection, making expanded and accessible testing for HCV — particularly among those born between 1945 and 1965 — a critical step in fighting this epidemic.”—The Chronic Liver Disease Foundation has endorsed a birth-cohort approach to expand screening for hepatitis C, which is currently being evaluated as a potential new CDC recommendation. A full position paper can be found here.